The purpose of this study was to determine the feasibility, safety, and efficacy of elective stenting with heparincoated Wiktor stents in patients with coronary artery disease. In experimental studies, heparin coating has been shown to prevent subacute thrombosis and restenosis. Recently, a new method of heparin coating was developed, resulting in a more stable and predictable heparin layer on stent devices. This trial constitutes the first in-human use of this coating procedure, applied on the well-known Wiktor stent device. Heparin-coated Wiktor stent implantation was performed in 132 consecutive patients (132 lesions) in a multicenter international trial from September 1996 to February 1997. Forty-three percent of patients had unstable angina, 33% had previous myocardial infarction, and 10% had diabetes mellitus. Patients were followed for 12 months for occurrence of major adverse cardiovascular events, and 96% of the eligible patients underwent quantitative angiographic control at 6 months. Stent deployment was successful in 95.5% of lesions. Minimal lumen diameter increased by 1.67 ؎ 0.48 mm (from 1.02 ؎ 0.38 mm before to 2.69 ؎ 0.37 mm after the stent implantation). Mean percent diameter stenosis decreased from 67.4 ؎ 11.3% before to 18.9 ؎ 7.7% after the intervention. A successful intervention (<50% diameter stenosis and no major adverse cardiac events within 30 days) occurred in 97% of the patients. The subacute thrombosis rate was 0.8%, which compares favorably with historical controls of this stent, and a low incidence of postprocedural increase in creatine kinase-MB was noted. At 6 months, event-free survival was 85% and angiographic restenosis rate was 22% with late loss of 0.78 ؎ 0.69 mm and a loss index of 0.48 ؎ 0.44. Heparin-coated Wiktor stents appeared to be an efficacious device to treat Benestent-like lesions, yielding angiographic and clinical results comparable to a heparin-coated PalmazSchatz stent. Despite its use in more complex lesions, the incidence of subacute thrombosis appeared to be lower than historical controls with a similar noncoated stent.
D
espite important advances in the clinical use of coronary stents, there still are important limitations to the general applicability of this technique. Even with the use of antiplatelet regimen with aspirin and ticlopidine, the risk of (sub)acute stent thrombosis remains important. 1 Furthermore, the use of ticlopidine carries a substantial risk of hematologic complications. 2 Therefore, a search for an effective method of stent surface passivation, eventually resulting in less thrombogenic risk and less need for concomitant medication, seems warranted. Data from animal work indicate that heparin-coated stents are associated with less acute thrombus formation, both in rabbit iliac arteries 3 and in a porcine coronary model. 4, 5 Previous clinical work with the heparin-coated Palmaz-Schatz stent (Johnson & Johnson, Interventional Systems, Warren, New Jersey) showed the safety and the efficacy of the heparin-coating technique. 6, 7 Recently, a new coating technique was developed, resulting in a more stable binding of heparin onto the surface (more temperature resistant and longer shelf time). This coating technique was applied on the Wiktor GX stent (Wiktor, Medtronic, Inc., Minneapolis, Minnesota). After several biochemical, morphologic, and animal tests, 8 it was decided to perform a multicenter clinical trial testing the safety and efficacy of this device in human coronary arteries.
METHODS

Wiktor GX balloon-expandable intracoronary stent:
The balloon-expandable Wiktor stent used in the present study is constructed of a single tantalum wire (diameter 0.127 mm) that is formed into a sinusoidal wave and wrapped into a helical coil structure. The prosthesis, 16 mm long, is premounted on a polyethylene balloon of a standard angioplasty catheter. The device was used under the Food and Drug Administration investigational device exemption status as part of a multicenter study. The study was approved by the ethical committee of each participating institution.
Heparin-coating procedure: The heparin is covalently bound to the tantalum stent surface according to the Hepamed (Medtronic Bakken Research Center, Maastricht, The Netherlands) coating procedure (in contrast with the classic Carmeda coating procedure). In short, poly(vinylsiloxane) is covalently bound to the tantalum surface as a first layer. Using a radical polymerization process, a co-polymer is grafted to the pendant vinyl groups of the poly(vinylsiloxane) layer. The result is a hydrophilic co-polymer covalently bound to the first layer. Polyethyleneimine (third layer) is covalently bound to the carboxyl groups of the co-polymer in such a way that the polyamine interpenetrates the grafted co-polymer. As a fourth and last layer, heparin is covalently coupled to the polyamine using a reducing agent. 9 Selection of patients: Eligible patients were those scheduled to undergo coronary angioplasty, who had 1 de novo lesion resulting in stable or unstable angina, without contraindications for platelet therapy with aspirin and ticlopidine, and who were suitable for stent implantation (lesions Յ12 mm in length and located in a vessel that was visually estimated at between Ն3 and Յ4.5 mm, supplying viable myocardium). Patients were excluded if a left main lesion was present, Thrombolysis In Myocardial Infarction (TIMI) flow was Ͻ2, if they had an acute myocardial infarction Ͻ7 days old, any thrombus present, an ostial lesion (Ͻ12 mm for right coronary artery, Ͻ5 mm for left coronary artery), diffuse coronary disease, previous bypass on target vessel, lesion located in bypass graft, left ventricular ejection fraction Ͻ40%, and a lesion located at a bifurcation (diameter side branch Ͼ50% of native vessel). The study was performed according to the Declaration of Helsinki and informed consent was obtained from all participating patients.
Implantation procedure: Before intervention, patients were pretreated with aspirin (Ն75 mg/day). In addition, a bolus of heparin (10,000 IU) was administered just before angioplasty, with supplemental boluses (5,000 IU) for each additional hour of procedural time. Ticlopidine was preferably started 24 hours before the procedure. Stent implantation was performed according to standard clinical practice by the femoral route. Predilation was performed in every lesion. Subsequently, a premounted heparin-coated Wiktor stent with a diameter equivalent to or slightly (Ͻ10%) greater than the mean reference diameter of the adjacent vessel was deployed at the nominal balloon inflation pressure. 10 If necessary, further inflations up to 12 atm (with the stent delivery balloon) or Ͼ12 atm (with another noncompliant or semicompliant balloon) were performed at the discretion of the investigator. 11 Heparin was discontinued immediately after the procedure and sheaths were removed on the same day. All patients were treated with aspirin (75 to 300 mg/day) and ticlopidine (250 to 500 mg/day) after the procedure. Ticlopidine was continued for Ն4 weeks, providing absence of drug reactions. Creatine kinase and creatine kinase-MB values were assessed in all patients at 12 and 24 hours.
Clinical and angiographic follow-up: Patients were seen at the outpatient clinic at 30 days and at 6 months (Ϯ 14 days) for interview, physical examination, and electrocardiograms. Hematologic monitoring was performed at 2 and 4 weeks. At 12 months, all patients were contacted (most by telephonic interview) for analysis of clinical events. At 6 months (before control angiography), an exercise test was performed. All eligible patients were scheduled for 6-month control angiography. Thus, in every patient an angiogram was performed at baseline, after intervention, and at 6-month follow-up. To standardize the method of data acquisition and analysis, all angiograms were analyzed in a core laboratory (Heart Core, Leiden, The Netherlands). The quantitative coronary angiographic measurements were assessed with the Cardiovascular Measurement System (QCA-CMS version 3.32, MEDIS, Leiden, The Netherlands). [12] [13] [14] End points: The primary end point of this study was to assess the 30-day subacute and/or acute thrombosis rate. Secondary end points were both clinical, occurrence of major adverse cardiac events (death, myocardial infarction, and repeat intervention), and angiographic (restenosis rate, acute gain and late loss, success rate). Subacute and/or acute thrombosis was defined as the angiographic documentation of a complete occlusion (TIMI flow 0 or 1) or the angiographic documentation of a flow-limiting thrombus (TIMI flow 1 or 2). Death was defined to include all deaths, irrespective of cause. Myocardial infarction was diagnosed if there were new pathologic Q waves according to the Minnesota code 15 and/or if there was an increase in serum creatine kinase to more than twice the normal value, along with increased myocardial isoenzyme levels. Repeat interventions were those involving a previously treated lesion following the initial procedure, which was judged to be complete when the guiding catheter was removed from the arterial sheath. Angiographic success rate was defined as a reduction in stenosis to Յ50%. Procedural success was defined as angiographic success without major adverse cardiac events during hospitalization. Optimal stent placement was defined as residual stenosis Ͻ20% after Wiktor stent placement as assessed by quantitative coronary angiography and TIMI 3 flow. Angiographic restenosis rate was defined as Ն50% diameter stenosis on follow-up angiography.
Statistical analysis: Continuous variables are expressed as means Ϯ SD. Discrete variables are expressed as counts and percentages.
RESULTS
Baseline characteristics: A total of 132 patients were enrolled at 10 European centers from September 1996 to February 1997. In 24 patients major violations regarding inclusion and exclusion criteria were observed, as assessed by an angiographic review committee. Protocol violations were (in ranking order): multivessel disease (n ϭ 18); presence of thrombus (n ϭ 3); diffuse disease (n ϭ 1); ostial lesion (n ϭ 1); and previous angioplasty (n ϭ 1). Mean age was 57 Ϯ Tables I and II. Stent implantation procedure: In total, 134 stent implantations were attempted in 132 patients (Table  III) . Of these, 128 stent deliveries were considered technically successful, yielding a stent delivery success rate of 96%. The 6 delivery failures were due to unability to cross the lesion. In 2 patients the stent had to be deployed proximal to the lesion. In 4 patients, the stent was removed; 3 of these patients were treated with additional angioplasty and in the fourth patient a Palmaz-Schatz stent could also not be deployed; this patient underwent elective bypass surgery. Mean stent size was 3.46 Ϯ 0.41 mm (3.0 to 4.5) with 80% of the stents mounted on a Յ3.5-mm balloon. The mean balloon inflation pressure during predilation was 9 Ϯ 3 atm; only 1 patient did not undergo predilation. In 87% of the patients Յ2 balloon inflations were performed for stent deployment. Mean stent implantation pressure was 11 Ϯ 3 atm (range 6 to 19) for a total inflation time of 63.4 Ϯ 41 seconds.
Clinical events: Four patients (3.1%) had a major adverse cardiac event in the first month after heparincoated Wiktor stent implantation (Table IV) . Three of these patients were protocol violators (multivessel disease [3 patients], thrombus [1 patient]). Two patients with multivessel disease died. The first patient, an 82-year-old woman, had a stent placed in the proximal right coronary artery. A few hours later, the patient became ischemic; control angiography showed a perfect stent result, but an acute occlusion of the distal circumflex artery. Attempts to reopen the circumflex artery resulted in contrast overload with pulmonary edema and cardiogenic shock. The second patient had significant 2-vessel disease with a thrombus at the dilation site before stenting. The patient had unevent- ful stenting but suddenly collapsed at home at day 5.
No autopsy was performed. One patient had a thrombotic stent occlusion 3 hours after stenting, probably related to an untreated distal dissection that became occlusive after the procedure. In this patient, 2 additional stents (1 NIR stent [Medinol, Natick, Massachusetts] and 1 AVE stent [Arterial Vascular Engineering, Santa Rosa, California]) were implanted distal to the treated site. One patient had a non-Q-wave myocardial infarction the day after the procedure. All the remaining patients (n ϭ 124) were event free at 30 days, resulting in an event-free rate of 97%. The 6-month target lesion revascularization rate was 17%. One patient underwent elective coronary artery bypass grafting for recurrent angina 6 weeks after stenting and repeat coronary angioplasty was performed in 15 patients (12%), resulting in an eventfree survival of 85%. Ninety-five percent of surviving patients were either asymptomatic or had mild stable angina (Canadian Cardiovascular Society class I or II).
At 12-month follow-up (98% complete) 4 additional reinterventions for revascularization in the target lesion were undertaken. Two patients underwent coronary artery bypass grafting and 2 patients were dilated, resulting in an event-free survival at 1 year of 84%.
Angiographic results: Quantitative coronary angiography in Ն1 angiographic projection was possible in 116 patients (94%) before stenting, in 119 patients (97%) after stenting, and in 110 patients (89%) at follow-up. Data on pre-and postprocedural reference diameters, minimal luminal diameter, and percent diameter stenosis are listed in Table V . When compared with Benestent II data these diameters are remarkably similar (Table VI) . The reference diameter was Ͻ3.0 mm in 38%, Ͻ2.75 mm in 21%, and Ͻ2.5 mm in 10% of the patients. The average diameter stenosis at baseline was 67%, which was reduced after stenting to 19% (range Ϫ16% to 42%). In all cases, final diameter stenosis was Ͻ50%, leading to angiographic success rate of 100%. An optimal stent placement was achieved in only 71 cases (60%). The mean stent-toartery dimension ratio was 1.11, defining a mean stent oversizing by 11%.
Six-month angiograms were obtained in 123 patients (96%), of which 110 films were suitable for quantitative coronary angiography. The restenosis rate was 22% (24 of 110 patients). Minimal luminal diameter increased from 1.02 mm before treatment to 1.92 mm at 6 months, representing a net gain of 0.89 mm. Late loss was calculated as 0.78 mm, with a loss index of 0.48. Of the 24 patients with Ͼ50% stenosis at follow up, only 10 patients were symptomatic; interestingly, 9 of 24 patients had a percent diameter stenosis at follow-up between 50% to 60% that was mostly diffuse but only 2 patients were symptomatic.
DISCUSSION
The present study assesses the utility of a new method of heparin coating, resulting in more predictable activity over time. It is the first prospective study using the heparin-coated Wiktor stent for the treatment of Benestent-like lesions. Although many patients (18.2%) did not meet the strict angiographic criteria defined in the protocol to fullfill the lesion characteristics as those included in the Benestent trial, it was decided to keep them in the analysis even if this could influence both the early and late clinical and/or angiographic results.
Principles of the heparin coating: Contact of blood with a foreign surface is known to result in a multiplicity of phenomena, including protein deposition and activation of complement system and clotting cascade, eventually leading to thrombus formation. Electropolishing of the stent resulting in passivation and a smooth surface has been shown to reduce the incidence of stent thrombosis. 16 Nevertheless, stent thrombosis remains a potential problem, particularly when treating total occlusion, acute myocardial infarction, or smaller vessels. Therefore, a number of materials are evaluated as potential thromboresistant stent coatings (hydrogel, polyurethanes). A heparincoated surface with its end attached to the stent proved to be superior in thrombosis models and was first used in the Benestent II study. 7 Heparin-coated surfaces were evaluated before in various devices where thromboresistance was of clinical value, such as arteriovenous shunts, arterial filters, oxygenators, and vascular endoprosthesis. [17] [18] [19] The principle anticoagulant mechanism of heparin is the interaction with antithrombin III, accelerating the inactivation of thrombin or other coagulation factors. The problem with surface coating is that the heparin molecule has to remain biologically active (i.e., the active sequence has to remain unaltered). For the present study, heparin was covalently bound to the tantalum stent surface according to the Hepamed coating procedure. In brief, this method results in a stronger and more stable binding of heparin to the stent surface, resulting in a more stable antithrombin III activity over time. 9 Heparin coating in the ticlopidine era: The Full Anticoagulation versus Aspirin and Ticlopidine (FAN-TASTIC) study has definitely shown a reduction of subacute stent occlusion for the Wiktor stent with the use of ticlopidine. 1 However, when closely examining the results, there was an incidence of 2.4% of acute stent occlusion in the antiplatelet group and a 3.7% incidence of non-Q-wave infarction (defined as an increase of creatine kinase Ͼ2 times upper limit of normal). In this study, a 0.8% rate of acute occlusion and 0.8% rate of non-Q-wave infarction both suggest a clinical benefit for the heparin-coated stent. However, it has to be admitted that in the FANTASTIC study all types of stent placement, elective and bailout, were allowed, whereas in the present study only Benestent-like lesions, at least in theory, could be treated. Further evidence for a possible effect of the heparin coating comes from the prospective creatine kinase and creatine kinase-MB data. In the present trial, the increase of creatine kinase/creatine kinase-MB was 0.8% (comparable to Benestent II), which compares favorably to other prospective nonheparin-coated stent trials (8% to 15%). 20 This apparent reduction in creatine kinase can be attributed to the heparin coating, although the lack of side branch occlusion with this rather open stent design could also explain this observation.
Role of heparin coating in stent restenosis: In this trial, as well as in the Benestent trial, the magnitude of restenosis, late loss, and loss index is similar to that observed in angiographic trials using noncoated stents (Table VI) . 21 The failure to prevent restenosis with heparin coating indicates that thrombin generation is not the sole activator of neointimal proliferation. Although thrombin has been shown to have potent direct and indirect mitogenic effects, 22 the results of this study indicate that restenosis after stent implantation is a multifaceted problem that cannot be overcome only by reducing or inhibiting early thrombus formation. 
